Disease Model Development and Phenotyping Project

疾病模型开发和表型分析项目

• 批准号: 10708111
• 负责人: Gareth R Howell
• 金额: $ 534.3万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-30 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708111
• 关键词: 3-Dimensional; Acceleration; Address; Affect; Age Months; Alleles; Alzheimer' s disease model; Alzheimer' s disease pathology; Amyloid beta-42; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animal Model; Biochemistry; Bioinformatics; Biological Assay; Biological Markers; Biological Models; Brain; CRISPR/Cas technology; Chronic; Clinic; Clinical Trials; Cognitive; Communities; Consumption; Coupled; Data; Development; Diet; Disease model; Environmental Risk Factor; Evaluation; Fatty acid glycerol esters; Female; Funding; Genetic; Genetic Risk; Genotype; Haplotypes; Heterogeneity; High Fat Diet; Hippocampus; Human; Image; Late Onset Alzheimer Disease; Ligands; Liquid substance; Long-Term Potentiation; MAPT gene; Magnetic Resonance Imaging; Medicine; Modeling; Mus; Mutation; PET/CT scan; Pathology; Phenotype; Polygenic Traits; Positron-Emission Tomography; Pre-Clinical Model; Preclinical Testing; Predictive Factor; Predisposition; Proteomics; Research; Risk; Risk Factors; Scheme; Synapses; TREM2 gene; Testing; Translating; Translations; United States Food and Drug Administration; Variant; Vertebral column; Work; age related; aged; amyloid imaging; apolipoprotein E-4; cognitive testing; comparison control; data management; design; digital; disease phenotype; efficacy testing; familial Alzheimer disease; genetic risk factor; genetic variant; improved; in vivo imaging; longitudinal design; male; metabolomics; model development; model organism; mouse genetics; mouse model; multiple omics; nano-string; neuroinflammation; neuron loss; neuropathology; novel; preclinical efficacy; preclinical study; risk variant; screening; sugar; synergism; tau aggregation; transcriptome; transcriptomics

PROJECT SUMMARY DISEASE MODEL DEVELOPMENT AND PHENOTYPING (DMP) PROJECT In the initial funding period, the DMP created and evaluated more than forty new models incorporating 33 LOAD- relevant alleles. This included a set of platform strains that incorporated humanized APOE4, Trem2*R47H and humanized Aβ sequence. Platform strains were evaluated from 4 to 24 months through the IU/JAX/PITT MODEL- AD phenotyping pipeline that included PET/CT, multi-omics (transcriptomics, proteomics and metabolomics), neuropathology, and fluid biomarker analysis. The first platform strain, LOAD1 (double homozygous for APOE4 and Trem2*R47H) showed primarily age-dependent affects and few genotype-specific effects. For our second platform strain, LOAD2 (triple homozygous for APOE4, Trem2*R47H and hAβ), we included a high fat/high sugar diet (HFD) group as an environmental risk factor. Compared to control mice, at 12 months, HFD-fed LOAD2 mice showed elevated levels of insoluble Aβ42, loss of neurons in the subiculum, reduced long-term potentiation (LTP), and reduced spine densities in the hippocampus. In addition to the platform models, 24 putative genetic risk variants identified by the Bioinformatics and Data Management core (BDMC) were introduced into LOAD1 or LOAD2 by CRISPR/Cas9 and evaluated by comparing brain transcriptomes to Accelerated Medicines Partnerships in AD (AMP-AD) data. The putative risk variants were located in both previously identified (e.g., Abca7, CR1, Plcg2, Mthfr and Epha1) as well as novel AD risk genes. Through this work, Abca7*A1527G, Plcg2*M28L and Mthfr*677C>T were prioritized for full characterization through our phenotyping pipeline. Collectively, these data support our overarching hypothesis that combinations of LOAD-relevant genetic and/or environmental risk factors, in the absence of familial AD (fAD) mutations, will induce hallmark AD pathologies in mice and therefore create improved mouse models for preclinical testing. In the renewal we will continue to evaluate novel LOAD models, with an increased focus on identifying models for the preclinical testing core (PTC). To achieve this, our phenotyping pipeline has been enhanced and incorporates a combined cross-sectional and longitudinal design, extensive biomarker analysis, MRI, additional PET ligands (e.g., for neuroinflammation and synapse loss), digital spatial profiling, and synaptic and cognitive assessment. We will first complete characterization of three prioritized LOAD strains as well as characterize a novel platform model LOAD3 (triple homozygous for APOE4, hAβ and a humanized MAPT allele) with and without HFD (Aim 1). Hyperphosphorylation and aggregation of TAU is a hallmark pathology for LOAD and absent in our current strains. Therefore, we will next evaluate four MAPT variants (N279K, P301L, R406W and S320F) that are predicted to increase susceptibility to TAU pathology (Aim 2). Finally, no single LOAD model is expected to represent the heterogeneity of human LOAD and we will therefore evaluate novel LOAD models based on polygenic risk analysis (BDMC, Aim 3). The DMP will continue to synergize with the BDMC and Preclinical Test Core (PTC) to develop more precise mouse models of LOAD and initiate preclinical testing.

项目概述疾病模型开发和表型（dmp）项目